Back to Search
HOWARD LANE, M.D.
M.D.
Ophthalmology Physician
NPI: 1366415135IndividualAccepts Medicare
Specialties, Licenses & Credentials
Ophthalmology PhysicianPrimary
Ophthalmology
Code: 207W00000X
212402(NY)
CMS Specialties
PrimaryOPHTHALMOLOGY
Education
OTHER
Class of 1992
Research & Publications (20)
Can specific pain symptoms help in the diagnosis of endometriosis? A cohort study of women with chronic pelvic pain.
PMID 19342028·Fertil Steril·2010
4-observational
Identification of euglenophycin--a toxin found in certain euglenoids.
PMID 19615398·Toxicon·2010
7-preclinical
Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates.
PMID 19417212·Blood·2009
7-preclinical
Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia.
PMID 18635704·J Psychopharmacol·2009
4-observational
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) treatment for Isaacs syndrome with depression.
PMID 19328218·Prog Neuropsychopharmacol Biol Psychiatry·2009
5-case
Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.
PMID 19569973·J Infect Dis·2009
3-trial
Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
PMID 19527517·Mol Cancer·2009
7-preclinical
Identification and characterization of CRF02_AG, CRF06_cpx, and CRF09_cpx recombinant subtypes in Mali, West Africa.
PMID 19182920·AIDS Res Hum Retroviruses·2009
8-other
Roles of state and trait anxiety in physical activity participation for adults with anxiety disorders.
PMID 19515629·J Formos Med Assoc·2009
8-other
Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes.
PMID 19331811·Exp Cell Res·2009
7-preclinical
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
PMID 19223496·Clin Cancer Res·2009
4-observational
Optimal targeting of the mTORC1 kinase in human cancer.
PMID 19233631·Curr Opin Cell Biol·2009
6-review
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
PMID 19228731·Clin Cancer Res·2009
7-preclinical
PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications.
PMID 18484086·Am J Med Genet B Neuropsychiatr Genet·2009
8-other
Reply to comments on "Optimizing early prediction for antipsychotic response in schizophrenia".
PMID 19593183·J Clin Psychopharmacol·2009
8-other
Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.
PMID 19098490·AIDS·2009
3-trial
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
PMID 19380449·J Clin Oncol·2009
3-trial
Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
PMID 19372546·Mol Cancer Ther·2009
8-other
Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels.
PMID 19617815·AIDS·2009
2-rct
HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.
PMID 19060209·Proc Natl Acad Sci U S A·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1981 MARCUS AVE STE E115
NORTH NEW HYDE PARK, NY 11042 - Phone
- (516) 627-5113
Quick Facts
- NPI
- 1366415135
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile